Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Transplant Proc ; 51(1): 80-82, 2019.
Article in English | MEDLINE | ID: mdl-30655150

ABSTRACT

Tumor load is often underdiagnosed on radiological examination previous to liver transplantation (LT) for hepatocarcinoma (CHC). Thus, post-liver transplant explant analysis is required following transplantation to assess the risk of the recurrence of CHC. The objectives were to compare the characteristics of CHC on pre-LT radiological examination and explant histology and validate three models for the prediction of recurrence based on data from a cohort of patients treated in our hospital. METHODS: A retrospective study was undertaken of 105 LTs for CHC performed in our unit between January 2006 and January 2015. The minimum follow-up was five years. The preoperative radiological tumor stage was compared to the explant-based histologic stage. Three prognostic models were validated using our cohort of patients. RESULTS: Following Milan's criteria, the tumor load was underdiagnosed on pre-LT radiological examination in 20 patients, which accounted for 19% of the total sample. The 5-year overall recurrence was 6.6% for scores <4 and 33.3% for scores ≥4 according to Decaens' model; 7% for scores ≤7 and 25% for scores >7 in the Up-to-Seven model; and 3.6% for PCRS ≤0, 27.8% for PCRS1-2, and 100% for PCRS≥3 according to Chan's model. The predictive model for 5-year recurrence after LT with the greatest area under the curve was Chan's model (0.813 [95% CI: 0.650-0.977]) versus Decaens' model (0.674 [95% CI: 0.483-0.866]) and the Up-to-Seven model (0.481 [95% CI: 0.296-0.667]). CONCLUSIONS: A pre-LT radiological examination leads to the underdiagnosis of tumor load, and the risk for recurrence must be recalculated following LT. In light of the results obtained, Chan's model is more accurate in predicting 5-year recurrence of CHC post-LT based on 3 levels of risk. New prognostic models are needed to optimize the prediction of recurrence after liver transplantation for hepatocarcinoma.


Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Liver Transplantation , Models, Statistical , Neoplasm Recurrence, Local , Adult , Aged , Carcinoma, Hepatocellular/surgery , Cohort Studies , Female , Humans , Liver Neoplasms/surgery , Liver Transplantation/adverse effects , Male , Middle Aged , Neoplasm Recurrence, Local/etiology , Prognosis , Retrospective Studies , Tumor Burden
4.
Clin Nutr ; 22(6): 577-83, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14613761

ABSTRACT

AIMS: The purpose of this study was to establish the relevance of several clinical factors associated with parenteral nutrition (PN) hypertriglyceridemia and to construct a predictive model for this complication. METHOD: This multicenter study included all patients with initial serum triglyceridemia <3 mmol and receiving a minimum of 7 days' PN therapy. The study ended for each patient when hypertriglyceridemia developed or PN was terminated. Two multivariate models were constructed, one to study the clinical factors and the second to predict plasma triglyceridemia. A total of 22 clinical factors studied as independent variables were included in the multiple-step regression models only when they showed a P-value over 0.1. Statistical significance was determined by the confidence interval of the odds ratio (OR) and the partial regression coefficient (b). RESULTS: The study included 260 patients from 14 hospitals. Lipid administration was 0.83+/-0.37 g/kg/day. Among the total, 68 patients (26.2%) showed hypertriglyceridemia. Variables included in both models were serum glucose (OR, 2.63; b, 0.06), renal failure (OR, 10.56; b, 1.70), corticoid administration >0.5 mg/kg (OR, 7.98; b, 0.97), pancreatitis (OR, 4.38; b, 0.64), sepsis (OR, 4.48; b, 0.24), lipids infused (OR, 3.03; b, 0.24) and heparin administration >3 mg/kg/day (OR, 0.11; b, -1.21). CONCLUSION: Although the rate of lipid infusion was low, certain clinical factors modified triglyceridemia. Nevertheless, relatively fast plasma clearance of lipids infused indicates that a reduction in lipid supply could be a quick, effective measure for controlling hypertriglyceridemia. Thus, careful monitoring of patients with clinical factors predicting risk in the model studied, with adjustment of lipid perfusion rates accordingly, is suggested to avoid hypertriglyceridemia.


Subject(s)
Hypertriglyceridemia/blood , Hypertriglyceridemia/epidemiology , Parenteral Nutrition/adverse effects , Adult , Cohort Studies , Female , Humans , Lipids/administration & dosage , Male , Models, Statistical , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Prospective Studies , Regression Analysis , Risk Factors , Triglycerides/blood
5.
Crit Care Med ; 28(3): 643-8, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10752808

ABSTRACT

OBJECTIVE: To determine whether early enteral feeding in a septic intensive care unit (ICU) population, using a formula supplemented with arginine, mRNA, and omega-3 fatty acids from fish oil (Impact), improves clinical outcomes, when compared with a common use, high protein enteral feed without these nutrients. DESIGN: A prospective, randomized, multicentered trial. SETTING: ICUs of six hospitals in Spain. PATIENTS: One hundred eighty-one septic patients (122 males, 59 females) presenting for enteral nutrition in an ICU. INTERVENTIONS: Septic ICU patients with Acute Physiology and Chronic Health Evaluation (APACHE) II scores of > or =10 received either an enteral feed enriched with arginine, mRNA, and omega-3 fatty acids from fish oil (Impact), or a common use, high protein control feed (Precitene Hiperproteico). MEASUREMENTS AND MAIN RESULTS: One hundred seventy-six (89 Impact patients, 87 control subjects) were eligible for intention-to-treat analysis. The mortality rate was reduced for the treatment group compared with the control group (17 of 89 vs. 28 of 87; p < .05). Bacteremias were reduced in the treatment group (7 of 89 vs. 19 of 87; p = .01) as well as the number of patients with more than one nosocomial infection (5 of 89 vs. 17 of 87; p = .01). The benefit in mortality rate for the treatment group was more pronounced for patients with APACHE II scores between 10 and 15 (1 of 26 vs. 8 of 29; p = .02). CONCLUSIONS: Immune-enhancing enteral nutrition resulted in a significant reduction in the mortality rate and infection rate in septic patients admitted to the ICU. These reductions were greater for patients with less severe illness.


Subject(s)
Bacteremia/prevention & control , Cross Infection/prevention & control , Enteral Nutrition/methods , Food, Formulated , Sepsis/diet therapy , APACHE , Arginine/therapeutic use , Bacteremia/epidemiology , Cross Infection/epidemiology , Fatty Acids, Omega-3/therapeutic use , Female , Humans , Immunity , Intensive Care Units , Length of Stay , Male , Middle Aged , Nucleotides/therapeutic use , Prospective Studies , Sepsis/immunology , Sepsis/mortality , Spain/epidemiology
6.
Eur J Respir Dis ; 67(2): 141-4, 1985 Aug.
Article in English | MEDLINE | ID: mdl-4054263

ABSTRACT

A 34-year-old man, previously diagnosed as having an idiopathic diffuse glomerulonephritis, developed an acute, fulminating pulmonary disease which fulfilled clinical, radiological and physiological criteria for ARDS. He also fulfilled criteria for the diagnosis of systemic lupus erythematosus. High-dose corticosteroid therapy, artificial respiration and hemodialysis were instituted and were followed by marked clinical, radiological and physiological improvement, returning to normal 15 days after admission. We discuss here the role of immune complexes in the pathogenesis of acute pulmonary vasculitis of lupus erythematosus and suggest a role of corticosteroid pulse therapy in treating ARDS of this etiology.


Subject(s)
Lupus Erythematosus, Systemic/complications , Respiratory Distress Syndrome/etiology , Acute Disease , Adult , Antigen-Antibody Complex/immunology , Glomerulonephritis/complications , Glomerulonephritis/immunology , Humans , Lupus Erythematosus, Systemic/immunology , Male , Methylprednisolone/therapeutic use , Prednisolone/therapeutic use , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/immunology
SELECTION OF CITATIONS
SEARCH DETAIL